Planet Microcap Podcast | Microcap Investing Strategies

For today's show, I invited on Eden Rahim, Portfolio Manager for the Next Edge Biotech and Life Sciences Opportunities Fund. It's been a bloodbath for biotech in the last two years - according to the S&P Biotechnology Select Industry Index, the sector has been down ~45-50%. At the same time, in 2023, also according to the S&P Biotechnology Select Industry Index, the sector is up about 4-5% already on the year (as of January 20, 2023). Whether this is a sign that things are looking up for biotech is still too early to tell, but I felt its worth discussing why its been hard times in biotech in 2021 and 2022. Eden and I also discuss what he's looking for amongst the biotech rubble, in particular, why it's so important to pay attention to how Phase 2b clinical trials are constructed. We close out with his biotech predications for 2023. For more information about Eden Rahim and Next Edge Capital, please visit: https://www.nextedgecapital.com/funds/next-edge-biotech-and-life-sciences-opportunities-fund/over